Cargando…

Value and specificity of rare diseases business model-is the pursuit of this societal priority sustainable?

Detalles Bibliográficos
Autores principales:	Dunoyer, M, Rollet, P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3504598/ http://dx.doi.org/10.1186/1750-1172-7-S2-A23

Ejemplares similares

Sustainable rare diseases business and drug access: no time for misconceptions
por: Rollet, Pierrick, et al.
Publicado: (2013)

Geriatrics lymphedema: priority in therapeutic choices
por: Michelini, S, et al.
Publicado: (2010)

The Problematic Role of Materialistic Values in the Pursuit of Sustainable Well-Being
por: Isham, Amy, et al.
Publicado: (2022)

Creating sustainable health care systems: Agreeing social (societal) priorities through public participation
por: Littlejohns, Peter, et al.
Publicado: (2019)

Is the pursuit of happiness the pursuit of homeostasis? A review on the modulatory functions of endorphins on human behavior
por: Conde Moreno, M., et al.
Publicado: (2022)

The emergence of the cause of rare diseases and rare disease patients’ movement
por: Huyard, Caroline
Publicado: (2012)

The disease business
por: May, Robin C
Publicado: (2000)

Value judgment of new medical treatments: Societal and patient perspectives to inform priority setting in The Netherlands
por: Nicolet, Anna, et al.
Publicado: (2020)

Rare thyroid diseases
por: Łącka, Katarzyna
Publicado: (2013)

Business analysis and market potential of drug screening technology for preventive and personalized therapy
por: Volchek, Igor V, et al.
Publicado: (2014)

Building sustainable legacies: the new frontier of societal value co-creation
por: Greenleaf Publishing
Publicado: (2013)

Biomarker Pursuit: Keeping Current With Novel Biomarkers in Hematology/Oncology
por: Faiman, Beth, et al.
Publicado: (2023)

Musculoskeletal health, wealth and business, and wider societal impact
por: Woolf, Anthony
Publicado: (2022)

Country's value priorities in health crisis: How dominant societal motivations shape COVID-19 severity
por: Ma, Mac Zewei, et al.
Publicado: (2023)

Vaccination risks in children with rare diseases
por: Barberi, Ignazio, et al.
Publicado: (2015)

Setting economic priorities for patient safety programs and patient safety research using case mix costing data
por: Jackson, T, et al.
Publicado: (2009)

Shifting priorities and employment choices among workers in Wales during the COVID-19 pandemic: a longitudinal analysis
por: Griffiths, Melda Lois, et al.
Publicado: (2022)

A priority paper for the societal and ethical aspects of synthetic biology
por: Schmidt, Markus, et al.
Publicado: (2009)

Sensitivity, specificity, positive predictive value, negative predictive value and accuracy of neuropathy diabetes score (NDS) compared with the Michigan neuropathy screening instrument (MNSI)
por: Nienov, Otto Henrique, et al.
Publicado: (2015)

Professional clinical guidelines for rare diseases: methodology
por: Kremp, Odile, et al.
Publicado: (2012)

Developing a national plan for rare diseases in Germany through concerted action: the national action league for people with rare diseases
por: Héon-Klin, Véronique, et al.
Publicado: (2012)

How personal values follow the societal lockdown due to COVID-19: Case of business students in Slovenia
por: Potocan, Vojko, et al.
Publicado: (2023)

Singleton-Merten Syndrome: a rare autoimmune disorder caused by a specific IFIH1 mutation
por: Buers, I, et al.
Publicado: (2015)

Development the societal preference-based utility value set for the Patient Health Questionnaire depression scale in Hungary
por: Balázs, P., et al.
Publicado: (2022)

The second French plan for rare diseases 2011-2014
por: Garcia, Alain, et al.
Publicado: (2012)

Compassionate use programmes for rare diseases: proposals for actions
por: Houÿez, François, et al.
Publicado: (2012)

Approaches in rare diseases and pediatrics across international boundaries
por: Liebman, Michael
Publicado: (2012)

Unleashing the crowd: collaborative solutions to wicked business and societal problems
por: Majchrzak, Ann, et al.
Publicado: (2019)

Novel human partner cell line for immortalisation of rare antigen-specific B cells in mAb development
por: Kaseko, Galina, et al.
Publicado: (2011)

The Meaning of Age or Generational Differences in U.S. Political Values and Priorities
por: Gonyea, Judith, et al.
Publicado: (2020)

Gene therapy for rare diseases – the case for acute intermittent Porphyria
por: Grosios, Konstantina
Publicado: (2014)

Children with rare diseases, is it true that they have an enhanced anesthesiological risk?
por: Sammartino, Maria, et al.
Publicado: (2015)

The optimal pressure of sustained inflation for alveolar recruitment
por: Qiu, HB, et al.
Publicado: (2002)

EPIRARE survey on activities and needs of rare disease registries in the European Union
por: Taruscio, Domenica, et al.
Publicado: (2012)

State of the art of rare disease activities in Europe: a EUCERD perspective
por: Aymé, Ségolène
Publicado: (2012)

Scope of centres of expertise for rare diseases in European countries where they exist
por: Rodwell, Charlotte, et al.
Publicado: (2012)

The Italian project to increase health professionals’ training and awareness on rare diseases
por: Bellagambi, Simona
Publicado: (2012)

PW03-012 – Unmet need in Behçet's disease: remission is rare
por: Alibaz-Oner, F, et al.
Publicado: (2013)

Testing a comprehensive model of implementation and sustained use for EBTs for PTSD: A national investigation in VA residential settings
por: Schnurr, Paula P, et al.
Publicado: (2015)

The political empowerment of rare disease patient advocates both at EU and national level
por: Andersen, Terkel
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_42qpblc29aa78jolbogi9959no